Article and Video CATEGORIES
TRANSCRIPT
Immunotherapy for Previously Treated Patients with Non-Small Cell Lung Cancer (NSCLC) Presented by Karen Reckamp, MD, MS Co-Director, Lung Cancer and Thoracic Oncology Program Medical Director, Clinical Research Operations City of Hope Comprehensive Cancer Center Duarte, California
I’m Karen Reckamp, I’m a medical director for Thoracic Oncology and the medical director for Clinical Research at the City of Hope Comprehensive Cancer Center in Duarte, California. The role of immunotherapy as second-line therapy for non-small cell lung cancer has been established. Most patients who do not receive immunotherapy, essentially checkpoint inhibition PD1 or PDL1 inhibition, as first-line therapy are eligible to receive it as second-line therapy after the standard first therapy. The immunotherapy has shown to improve overall survival for patients over the previous standard of care Docetaxel. Most patients at this point receive immunotherapy being anti-PD1 or anti-PDL1 immunotherapy as second-line therapy. The role of Docetaxel and Ramucirumab has thus shifted as in the initial trial these drugs were used in the setting post first-line chemotherapy. Generally, these drugs are used after immunotherapy as the second systemic cytotoxic therapy. For patients who are not able to tolerate immunotherapy or patients who have active auto-immune phenomenon, the combination of Ramucirumab and Docetaxel is an option and again does provide improved overall survival, improved progression-free survival, and increases tumor shrinkage over Docetaxel alone in patients with non-small cell lung cancer.
We would like to thank the following companies for their support of this program
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi Revtoby, Welcome to Grace. I'm sorry you and your wife are worried about cancer but we couldn't say whether or not your wife's leison is cancer no matter how much...
Canyil, I'm sorry your father and you are going through this. While we can't give urgent help we are her to help offer info and resources to help make the best...
Hello and welcome to Grace. I'm sorry you're going through this worry. It is normal to watch a small very slow-growing solid nodule with once-a-year CT scans. Anything less than a...
Thanks you very much. So in summary the course of action taken suggested by lung specalist (re scan in 12 months) seems appropriate? And a PET at this stage is probably...
I can't say what is appropriate for you that's only something your professionals with all your information can do. However, when someone has a solid nodule less than a cm that...